BBIO4:01 PMBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)bridgebio.com
BBIO7:30 AMAcoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CMbridgebio.com
BBIO7:30 AMBridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launchesbridgebio.com
BBIO4:00 PMBridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with AchondroplasiaTrial Results • Phase 3bridgebio.com
BBIO4:31 PMBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)bridgebio.com
BBIO7:30 AMBridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026Presentation / Abstract • Phase 3bridgebio.com
BBIO7:30 AMBridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9bridgebio.com
BBIO9:30 AMAcoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failurebridgebio.com
BBIO4:01 PMBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)bridgebio.com
BBIO7:30 AMBEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazilbridgebio.com
BBIO7:30 AMBridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECEPresentation / Abstract • Phase 3bridgebio.com
BBIO7:30 AMBridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026Presentation / Abstractbridgebio.com
BBIO7:30 AMBridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ETbridgebio.com
BBIO7:30 AMBridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. Whitebridgebio.com
BBIO7:30 AMBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)bridgebio.com